Aviragen Therapeutics, Inc.
Investor Relations Department
2500 Northwinds Parkway
Suite 100
Alpharetta, GA 30009
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: AVIR	
Last Trade:	0.56
Trade Time:	3:56 PM ET Nov 17, 2017
Change:	-0.01 (-1.651%)
Day Range	0.55 - 0.58
52-Week Range	0.43 - 1.60
Volume	165,239

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: vapendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; enzaplatovir (BTA585), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, an antiviral treatment for condyloma caused by human papill... (more)

Stock Information

Press Releases [View all]

Nov 2, 2017
Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results

Oct 30, 2017
Aviragen Therapeutics and Vaxart Enter into Merger Agreement

Aug 31, 2017
Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results

May 4, 2017
Aviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Results

Apr 4, 2017
Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update

Financials [View all]

First Quarter Financial Results

Sep 1, 2017
Annual Report (10-K)

Sep 27, 2016
Proxy Statement (DEF 14A)

Nov 7, 2017
Quarterly Report (10-Q)

May 8, 2017
Quarterly Report (10-Q)

Feb 6, 2017
Quarterly Report (10-Q)